Table 1 Table displaying distribution of variables between MDS-RS, MDS-RS-SLD, and MDS-RS-MLD

Age (years)

73 (44–88)

73 (47–88)

72 (44–81)

0.22

No. of males

50 (66)

36 (63)

14 (74)

0.4

Hb; gm/dl

9.3 (5.8–14.4)

9.3 (5.8–13.4)

10 (7.8–14.4)

0.17

WBC count x 10⁹ per liter

5.1 (1.2–17.6)

5.7 (2.2–17.6)

4.4 (1.2–9.4)

0.02 *

ANC x 10⁹ per liter

3.06 (0.3–12.5)

3.2 (0.6–12.5)

2.13 (0.3–6.3)

0.02 *

Platelet count x 10⁹ per liter

237 (7–819)

255 (7–819)

202 (27–438)

0.05 *

BM ringed sideroblasts

35 (10–80)

50 (10–80)

20 (15–70)

0.004 *

BM blasts

1(0–4)

1(0–4)

1(0–3)

0.6

Abnormal karyotype (R-IPSS intermediate, poor and very poor cytogenetic risk groups)

6 (8)

4 (8)

2 (11)

0.5

IPSS cytogenetic risk groups

Good

69 (91)

52 (91)

17 (11)

0.5

Intermediate

2 (3)

2 (4)

0(0)

Poor

5 (6)

3 (5)

2 (11)

R-IPSS cytogenetic risk groups

Very good

2 (3)

1 (2)

1 (5)

0.6

Good

67 (88)

51 (89)

16 (84)

Intermediate

2 (3)

2 (4)

0(0)

Poor

4 (5)

2 (4)

2 (11)

Very poor

1 (1)

1 (2)

0(0)

SF3B1

49 (77)

41 (82)

8 (57)

0.06

ASXL1

10 (16)

6 (12)

4 (29)

0.15

DNMT3A

8 (13)

8 (16)

0(0)

0.04 *

TET2

4 (6)

4 (8)

0(0)

0.2

TP53

3 (5)

3 (6)

0(0)

0.2

IDH1

2 (3)

2 (4)

0(0)

0.3

SRSF2

1 (2)

1 (2)

0(0)

–

Others (PTPN11, ZRSR2, CSF3R, U2AF1)

4 (6)

4 (8)

0(0)

–

HMA treatment

5 (7)

2 (4)

3 (16)

0.2

Immunomodulatory treatment (Lenalidomide)

1 (1)

1 (2)

0(0)

0.83

Allogeneic HSCT

2 (3)

1 (2)

1 (5)

0.16

Leukemic transformation

2 (3)

1 (2)

1 (5)

0.34

Overall survival; median months (range)

46 (0–190)

47 (0–190)

44 (6–123)

0.2